[HTML][HTML] First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
…, ST Kiros, A Rocca, F Lagi… - The Journal of …, 2021 - Am Soc Clin Investig
The characterization of the adaptive immune response to COVID-19 vaccination in individuals
who recovered from SARS-CoV-2 infection may define current and future clinical practice. …
who recovered from SARS-CoV-2 infection may define current and future clinical practice. …
Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review
M Piccica, F Lagi, A Bartoloni… - Journal of Travel …, 2021 - academic.oup.com
Rationale for Review We performed a systematic review of the literature to investigate the
efficacy and safety of pentamidine isethionate for the treatment of human tegumentary and …
efficacy and safety of pentamidine isethionate for the treatment of human tegumentary and …
[HTML][HTML] The burden of Clostridioides difficile infection during the COVID-19 pandemic: a retrospective case-control study in Italian hospitals (CloVid)
…, A Ferraresi, C Fornabaio, S Grasselli, F Lagi… - Journal of clinical …, 2020 - mdpi.com
Data on the burden of Clostridioides difficile infection (CDI) in Coronavirus Disease 2019 (COVID-19)
patients are scant. We conducted an observational, retrospective, multicenter, 1:3 …
patients are scant. We conducted an observational, retrospective, multicenter, 1:3 …
[HTML][HTML] Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020
F Lagi, M Piccica, L Graziani, I Vellere, A Botta… - …, 2020 - eurosurveillance.org
We analysed the first 84 coronavirus disease (COVID-19) patients hospitalised in an infectious
and tropical disease unit in Florence, Italy, over 30 days after the start of the COVID-19 …
and tropical disease unit in Florence, Italy, over 30 days after the start of the COVID-19 …
Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study
Background The early identification of patients at risk of clinical deterioration is of interest
considering the timeline of COVID-19 after the onset of symptoms. Objective The aim of our …
considering the timeline of COVID-19 after the onset of symptoms. Objective The aim of our …
[HTML][HTML] SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies
…, P Farahvachi, L Zammarchi, F Lagi… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Immunization against SARS-CoV-2, the causative agent of COVID-19, occurs
via natural infection or vaccination. However, it is currently unknown how long infection- or …
via natural infection or vaccination. However, it is currently unknown how long infection- or …
Tubercular prosthetic joint infection: two case reports and literature review
S Veloci, J Mencarini, F Lagi, G Beltrami… - Infection, 2018 - Springer
Purpose Tubercular prosthetic joint infection (TB-PJI) is an uncommon complication. Lack of
evidence of systemic tuberculosis and clinical suspicion could bring a delay in the time of …
evidence of systemic tuberculosis and clinical suspicion could bring a delay in the time of …
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE …
…, B Rossetti, A Ciccullo, L Oreni, F Lagi… - HIV …, 2021 - Wiley Online Library
Objectives The aim of the present study was to compare the efficacy and durability of
treatment switch to two‐drug (2DR) vs. three‐drug (3DR) integrase inhibitor (InSTI)‐based …
treatment switch to two‐drug (2DR) vs. three‐drug (3DR) integrase inhibitor (InSTI)‐based …
Efficacy and tolerability of dolutegravir and two nucleos (t) ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients
…, C Picarelli, R De Marco, MV Cossu, F Lagi… - Aids, 2017 - journals.lww.com
Despite the evidence emerged from phase III clinical trials [2], limited data support the use
of dolutegravir-based regimens in highly treatment-experienced, virologically suppressed …
of dolutegravir-based regimens in highly treatment-experienced, virologically suppressed …
Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: An Italian multicentre real-life experience
…, M Spinicci, A Botta, V Bianco, F Lagi… - Journal of …, 2023 - academic.oup.com
Background Cefiderocol is a novel siderophore cephalosporin with promising activity
against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive …
against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive …